Researchers Report that Phenoxodiol is Producing Signfiicant Anti-Cancer Responses in Women with Gynecological Cancers
Posted Oct 01 2008 8:20pm
Researchers from YaleUniversity's School of Medicine have reported updated results from twoclinical studies they are conducting in women with late-stage ovarian cancerand in women with early-stage cancer of the cervix and vagina.
These data were presented on Saturday October 22, 2005 by Gil Mor, M.D.,Ph.D., associate professor of obstetrics, gynecology and reproductivesciences, Yale University School of Medicine, at the 11th World Congress onthe Menopause, International Menopause Society in Buenos Aires, Argentina, andhas been claimed as a breakthrough in management of these highly aggressivecancers by the use of the investigational anti-cancer drug, phenoxodiol (PXD).
These data were presented on Saturday October 22, 2005 by Gil Mor, M.D.,Ph.D., associate professor of obstetrics, gynecology and reproductivesciences, Yale University School of Medicine, at the 11th World Congress onthe Menopause, International Menopause Society in Buenos Aires, Argentina, andhas been claimed as a breakthrough in management of these highly aggressivecancers by the use of the investigational anti-cancer drug, phenoxodiol (PXD).
Read release here